<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220854</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-16-12436</org_study_id>
    <secondary_id>P30CA016059</secondary_id>
    <nct_id>NCT03220854</nct_id>
  </id_info>
  <brief_title>SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx</brief_title>
  <official_title>Phase 2 Clinical Trial of Stereotactic Radiotherapy (SRT) and PD-1 or PD-L1 Inhibiting Therapy for Treatment of Advanced Solid Tumors After Disease Control on PD-1 or PD-L1 Inhibiting Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if having radiation therapy and continuing&#xD;
      immunotherapy can improve the benefit of immunotherapy. There have been reports of patients&#xD;
      who were treated with radiation therapy that not only caused the treated tumors to shrink or&#xD;
      stop growing, but also resulted in tumors that had not been treated in other parts of the&#xD;
      body to shrink or stop growing. This effect is thought to be brought about by cells in the&#xD;
      body's immune system that become active as a result of the effects of radiation therapy. If&#xD;
      radiation therapy can stimulate the immune system, it may be possible for immunotherapy to be&#xD;
      helpful again in treating a cancer that the immunotherapy drug helped treat before. This&#xD;
      study will also check if receiving immunotherapy at the end of radiation therapy has any&#xD;
      effect on the side effects of radiation therapy or immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stereotactic radiotherapy (SRT) will be delivered in up to 10 treatment fractions over 1 to 2&#xD;
      weeks. Patients will continue to receive the same FDA-approved programmed death receptor-1&#xD;
      (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor that they had been receiving at the&#xD;
      time of disease progression through 52 weeks following completion of SRT.&#xD;
&#xD;
      Correlative blood samples will be collected at baseline, prior to the second SRT fraction,&#xD;
      after the last SRT fraction (on the same day), and at 8, 24, and 52 weeks after the last SRT&#xD;
      fraction. These samples will be used to determine the mechanistic immunologic effects of&#xD;
      therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Actual">July 21, 2021</completion_date>
  <primary_completion_date type="Actual">January 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Steriotactic Radiotherapy followed by a commercially available PD-1 or PD-L1 inhibitor drug</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Improved Disease Control</measure>
    <time_frame>Up to 24 weeks following SRT</time_frame>
    <description>Number of patients with improved disease control at 24 weeks following RT [Time Frame: up to 24 weeks following RT] 1a. Number of participants with improved disease control (SD, PR or CR) at 24 weeks per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) 1b. For participants enrolled with brain metastases: number of participants with improved disease (SD, PR or CR) control at 24 weeks per per Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Alive and Free From Progression at 24 Weeks Following SRT Per Unidimensional Immune-related Response Criteria (irRC)</measure>
    <time_frame>Up to 24 weeks following SRT</time_frame>
    <description>Number of participants alive and without progression (irSD+irPR+irCR) at 24 weeks post-RT per unidimensional immune-related response criteria (irRC)&#xD;
1b. For participants enrolled with brain metastases: number of participants alive and without progression (SD+PR+CR) at 24 weeks post-RT per immune Response Assessment in Neuro-Oncology (iRANO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Response in Irradiated Tumor Sites</measure>
    <time_frame>Up to 24 weeks following SRT</time_frame>
    <description>Number of participants with treatment response in irradiated tumor sites at 24 weeks post-RT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Response in Non-irradiated Tumor Sites</measure>
    <time_frame>Up to 24 weeks post-RT</time_frame>
    <description>Number of participants with treatment response in non-irradiated tumor sites at 24 weeks post-RT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Alive</measure>
    <time_frame>2 years following SRT</time_frame>
    <description>Number of patients who are alive at 2 years after completion of SRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3 or Greater Toxicity</measure>
    <time_frame>Through 8 weeks following SRT</time_frame>
    <description>Number of participants with grade 3 or greater toxicity from the regimen through 8 weeks following RT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Immune-related Toxicity From the Regimen</measure>
    <time_frame>Up to 2 years following RT</time_frame>
    <description>Number participants with immune-related AEs (irAEs) that require both checkpoint-inhibitor discontinuation and initiation of steroids reported per CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiobiological Signatures Associated With the Regimen</measure>
    <time_frame>Up to 52 weeks post SRT</time_frame>
    <description>Number participants with samples collected and number of participants with samples analyzed for immunologic effects of the regimen</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>A: SBRT (body) irradiation only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Patients receiving SBRT and SRS (body and brain) irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Patients receiving SRS (brain) irradiation only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy</intervention_name>
    <description>Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.</description>
    <arm_group_label>A: SBRT (body) irradiation only</arm_group_label>
    <arm_group_label>B: Patients receiving SBRT and SRS (body and brain) irradiation</arm_group_label>
    <arm_group_label>C: Patients receiving SRS (brain) irradiation only</arm_group_label>
    <other_name>SRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological: humanized anti-PD-1 monoclonal antibody</intervention_name>
    <description>Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration</description>
    <arm_group_label>A: SBRT (body) irradiation only</arm_group_label>
    <arm_group_label>B: Patients receiving SBRT and SRS (body and brain) irradiation</arm_group_label>
    <arm_group_label>C: Patients receiving SRS (brain) irradiation only</arm_group_label>
    <other_name>PD-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological: humanized anti-PD-L1 monoclonal antibody</intervention_name>
    <description>Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration</description>
    <arm_group_label>A: SBRT (body) irradiation only</arm_group_label>
    <arm_group_label>B: Patients receiving SBRT and SRS (body and brain) irradiation</arm_group_label>
    <arm_group_label>C: Patients receiving SRS (brain) irradiation only</arm_group_label>
    <other_name>PD-L1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically-proven diagnosis of a solid tumor malignancy&#xD;
&#xD;
          -  One of the following criteria must be met:&#xD;
&#xD;
          -  Clinical or radiographic evidence of disease control (defined as best response of&#xD;
             stable disease (SD) or partial response (PR) or combination of both for ≥ 16 weeks)&#xD;
             without evidence of complete response (CR) or progression OR&#xD;
&#xD;
          -  Clinical or radiographic evidence of disease progression during treatment with PD-1 or&#xD;
             PD-L1 inhibiting therapy, following previous tumor response (CR, PR, or SD for ≥ 16&#xD;
             weeks) to PD-1 or PD-L1 inhibiting therapy, and, for patients who discontinued PD-1 or&#xD;
             PD-L1 inhibiting therapy during response to therapy, disease progression must have&#xD;
             occurred following at least 8 weeks of re-treatment with PD-1 or PD-L1 inhibiting&#xD;
             therapy Note: Both the treating medical oncologist and radiation oncologist must be in&#xD;
             agreement with determination of disease progression.&#xD;
&#xD;
          -  Administration of a PD-1 or PD-L1 inhibitor within 60 days prior to study registration&#xD;
&#xD;
          -  Determination by the treating radiation oncologist that the patient is a candidate for&#xD;
             SRT (ie, radiation therapy with a stereotactic setup) Note: All brain metastases will&#xD;
             receive stereotactic radiotherapy (SRT).&#xD;
&#xD;
          -  The total number of tumors requiring SRT must be ≤ 5 Note: Regardless of the number of&#xD;
             brain metastases that will be treated with SRT, the brain metastases will be&#xD;
             considered to be one tumor.&#xD;
&#xD;
          -  Measurable disease by RECIST v1.1 that will not undergo SRT and that is amenable to&#xD;
             monitoring Note: all brain metastases will receive SRT. Therefore, a patient with&#xD;
             brain metastases that will be treated with SRT must also have extracranial disease&#xD;
             that will not undergo SRT and that is amenable to monitoring&#xD;
&#xD;
          -  Determination by the treating medical oncologist that the patient is a candidate to&#xD;
             continue the PD-1 or PD-L1 inhibiting therapy that had previously provided disease&#xD;
             control&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Karnofsky Performance Status score of ≥ 60 %&#xD;
&#xD;
          -  A woman of childbearing potential (WCBP), defined as a woman who is &lt; 60 years of age&#xD;
             and has not had a hysterectomy, must have a documented negative serum pregnancy test&#xD;
             within 14 days prior to initiating study treatment&#xD;
&#xD;
          -  Ability to understand and willingness to sign the consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other anti-cancer therapy administered between the time of tumor response to PD-1 or&#xD;
             PD-L1 therapy and time of study enrollment Note: Patients treated with a combination&#xD;
             of PD-1 or PD-L1 inhibiting therapy and other immunotherapy are eligible; patients&#xD;
             taking hormonal anti-cancer therapies or steroids for central nervous system (CNS)&#xD;
             edema management that, in the opinion of the investigator, are appropriate to continue&#xD;
             are eligible.&#xD;
&#xD;
          -  Any prior PD-1/PD-L1 therapy-related AE that, in the opinion of the investigator,&#xD;
             warrants exclusion from participation in this trial&#xD;
&#xD;
          -  Administration of any investigational agent within 4 weeks prior to initiating study&#xD;
             treatment&#xD;
&#xD;
          -  Known active hepatitis B or C&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Medical, psychological, or social condition that, in the opinion of the investigator,&#xD;
             may increase the patient's risk or limit the patient's adherence with study&#xD;
             requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Urdaneta, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <results_first_submitted>December 17, 2020</results_first_submitted>
  <results_first_submitted_qc>January 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2021</results_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03220854/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>No participants enrolled in Arm B.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>A: Patients Receiving SBRT (Body) Irradiation Only</title>
          <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
        </group>
        <group group_id="P2">
          <title>B: Patients Receiving SBRT and SRS (Body and Brain) Irradiation</title>
          <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
        </group>
        <group group_id="P3">
          <title>C: Patients Receiving SRS (Brain) Irradiation Only</title>
          <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No participants enrolled on Arm B</population>
      <group_list>
        <group group_id="B1">
          <title>A: Patients Receiving SBRT (Body) Irradiation Only</title>
          <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
        </group>
        <group group_id="B2">
          <title>B: Patients Receiving SBRT and SRS (Body and Brain) Irradiation</title>
          <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
        </group>
        <group group_id="B3">
          <title>C: Patients Receiving SRS (Brain) Irradiation Only</title>
          <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="59" upper_limit="71"/>
                    <measurement group_id="B3" value="67" lower_limit="67" upper_limit="67"/>
                    <measurement group_id="B4" value="67.8" lower_limit="59" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Improved Disease Control</title>
        <description>Number of patients with improved disease control at 24 weeks following RT [Time Frame: up to 24 weeks following RT] 1a. Number of participants with improved disease control (SD, PR or CR) at 24 weeks per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) 1b. For participants enrolled with brain metastases: number of participants with improved disease (SD, PR or CR) control at 24 weeks per per Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM)</description>
        <time_frame>Up to 24 weeks following SRT</time_frame>
        <population>No participants enrolled in Arm B</population>
        <group_list>
          <group group_id="O1">
            <title>A: SBRT (Body) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
          </group>
          <group group_id="O2">
            <title>B: Patients Receiving SBRT and SRS (Body and Brain) Irradiation</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
          </group>
          <group group_id="O3">
            <title>C: Patients Receiving SRS (Brain) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Improved Disease Control</title>
          <description>Number of patients with improved disease control at 24 weeks following RT [Time Frame: up to 24 weeks following RT] 1a. Number of participants with improved disease control (SD, PR or CR) at 24 weeks per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) 1b. For participants enrolled with brain metastases: number of participants with improved disease (SD, PR or CR) control at 24 weeks per per Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM)</description>
          <population>No participants enrolled in Arm B</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1a: Number of participants with improved disease control</title>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression at or before 24 Weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1b: Participants enrolled with brain metastases number of participants with improved disease control</title>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Group A participants did not receive brain irradiation</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Group A participants did not receive brain irradiation</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Group A participants did not receive brain irradiation</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression at or before 24 Weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Group A participants did not receive brain irradiation</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Group A participants did not receive brain irradiation</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Alive and Free From Progression at 24 Weeks Following SRT Per Unidimensional Immune-related Response Criteria (irRC)</title>
        <description>Number of participants alive and without progression (irSD+irPR+irCR) at 24 weeks post-RT per unidimensional immune-related response criteria (irRC)&#xD;
1b. For participants enrolled with brain metastases: number of participants alive and without progression (SD+PR+CR) at 24 weeks post-RT per immune Response Assessment in Neuro-Oncology (iRANO)</description>
        <time_frame>Up to 24 weeks following SRT</time_frame>
        <population>No participants were enrolled in Arm B</population>
        <group_list>
          <group group_id="O1">
            <title>A: Patients Receiving SBRT (Body) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
          </group>
          <group group_id="O2">
            <title>B: Patients Receiving SBRT and SRS (Body and Brain) Irradiation</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
          </group>
          <group group_id="O3">
            <title>C: Patients Receiving SRS (Brain) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive and Free From Progression at 24 Weeks Following SRT Per Unidimensional Immune-related Response Criteria (irRC)</title>
          <description>Number of participants alive and without progression (irSD+irPR+irCR) at 24 weeks post-RT per unidimensional immune-related response criteria (irRC)&#xD;
1b. For participants enrolled with brain metastases: number of participants alive and without progression (SD+PR+CR) at 24 weeks post-RT per immune Response Assessment in Neuro-Oncology (iRANO)</description>
          <population>No participants were enrolled in Arm B</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1a. Number of participants alive and without progression</title>
              <category_list>
                <category>
                  <title>Progression Free Survival per irRC at 24 wks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression per irRC at or before 24 Weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1b.For participants enrolled with brain metastases</title>
              <category_list>
                <category>
                  <title>Progression Free Survival per irRC at 24 wks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Group A participants did not receive brain irradiation</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression per irRC at or before 24 Weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Group A participants did not receive brain irradiation</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Group A participants did not receive brain irradiation</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Response in Irradiated Tumor Sites</title>
        <description>Number of participants with treatment response in irradiated tumor sites at 24 weeks post-RT.</description>
        <time_frame>Up to 24 weeks following SRT</time_frame>
        <population>No participants enrolled on Arm B.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Patients Receiving SBRT (Body) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
          </group>
          <group group_id="O2">
            <title>B: Patients Receiving SBRT and SRS (Body and Brain) Irradiation</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
          </group>
          <group group_id="O3">
            <title>C: Patients Receiving SRS (Brain) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Response in Irradiated Tumor Sites</title>
          <description>Number of participants with treatment response in irradiated tumor sites at 24 weeks post-RT.</description>
          <population>No participants enrolled on Arm B.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response at Irradiated Sites</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response at Irradiated Sites</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease at Irradiated Sites</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not assessed at week 24 due to overall progression</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Response in Non-irradiated Tumor Sites</title>
        <description>Number of participants with treatment response in non-irradiated tumor sites at 24 weeks post-RT</description>
        <time_frame>Up to 24 weeks post-RT</time_frame>
        <population>No participants enrolled on Arm B</population>
        <group_list>
          <group group_id="O1">
            <title>A: SBRT (Body) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
          </group>
          <group group_id="O2">
            <title>B: Patients Receiving SBRT and SRS (Body and Brain) Irradiation</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
          </group>
          <group group_id="O3">
            <title>C: Patients Receiving SRS (Brain) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Response in Non-irradiated Tumor Sites</title>
          <description>Number of participants with treatment response in non-irradiated tumor sites at 24 weeks post-RT</description>
          <population>No participants enrolled on Arm B</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response at non-irradiated sites</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response at non-irradiated sites</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease at non-irradiated sites</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression at non-irradiated sites at or before 24 weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Alive</title>
        <description>Number of patients who are alive at 2 years after completion of SRT</description>
        <time_frame>2 years following SRT</time_frame>
        <posting_date>07/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3 or Greater Toxicity</title>
        <description>Number of participants with grade 3 or greater toxicity from the regimen through 8 weeks following RT</description>
        <time_frame>Through 8 weeks following SRT</time_frame>
        <population>No participants enrolled in Arm B</population>
        <group_list>
          <group group_id="O1">
            <title>A: Patients Receiving SBRT (Body) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
          </group>
          <group group_id="O2">
            <title>B: Patients Receiving SBRT and SRS (Body and Brain) Irradiation</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
          </group>
          <group group_id="O3">
            <title>C: Patients Receiving SRS (Brain) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Greater Toxicity</title>
          <description>Number of participants with grade 3 or greater toxicity from the regimen through 8 weeks following RT</description>
          <population>No participants enrolled in Arm B</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Immune-related Toxicity From the Regimen</title>
        <description>Number participants with immune-related AEs (irAEs) that require both checkpoint-inhibitor discontinuation and initiation of steroids reported per CTCAE v5.0</description>
        <time_frame>Up to 2 years following RT</time_frame>
        <population>No participants enrolled on Arm B</population>
        <group_list>
          <group group_id="O1">
            <title>A: Patients Receiving SBRT (Body) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
          </group>
          <group group_id="O2">
            <title>B: Patients Receiving SBRT and SRS (Body and Brain) Irradiation</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
          </group>
          <group group_id="O3">
            <title>C: Patients Receiving SRS (Brain) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immune-related Toxicity From the Regimen</title>
          <description>Number participants with immune-related AEs (irAEs) that require both checkpoint-inhibitor discontinuation and initiation of steroids reported per CTCAE v5.0</description>
          <population>No participants enrolled on Arm B</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Participants with immune-related AEs (irAEs)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Participants with no immune related AE's (irAEs)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiobiological Signatures Associated With the Regimen</title>
        <description>Number participants with samples collected and number of participants with samples analyzed for immunologic effects of the regimen</description>
        <time_frame>Up to 52 weeks post SRT</time_frame>
        <population>No participants enrolled on Arm B</population>
        <group_list>
          <group group_id="O1">
            <title>A: Patients Receiving SBRT (Body) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
          </group>
          <group group_id="O2">
            <title>B: Patients Receiving SBRT and SRS (Body and Brain) Irradiation</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
          </group>
          <group group_id="O3">
            <title>C: Patients Receiving SRS (Brain) Irradiation Only</title>
            <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiobiological Signatures Associated With the Regimen</title>
          <description>Number participants with samples collected and number of participants with samples analyzed for immunologic effects of the regimen</description>
          <population>No participants enrolled on Arm B</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number of participants with samples collected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of participants with samples analyzed for immunologic effects of the regimen</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of participants with no samples collected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data was collected from the time of first SRT fraction and continued until 8 weeks following completion of SRT.</time_frame>
      <desc>There were no participants enrolled on Arm B.</desc>
      <group_list>
        <group group_id="E1">
          <title>A: Patients Receiving SBRT (Body) Irradiation Only</title>
          <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations</description>
        </group>
        <group group_id="E2">
          <title>B: Patients Receiving SBRT and SRS (Body and Brain) Irradiation</title>
          <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
        </group>
        <group group_id="E3">
          <title>C: Patients Receiving SRS (Brain) Irradiation Only</title>
          <description>Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE 5.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphocyte Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Incomplete objectives due to early closure to accrual of trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alfredo I Urdaneta</name_or_title>
      <organization>Virginia Commonwealth University Massey Cancer Center</organization>
      <phone>(804) 828-0450</phone>
      <email>MasseyRadOnc@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

